RedHill Biopharma (RDHL) Non-Current Deffered Revenue (2018 - 2025)
RedHill Biopharma (RDHL) reported Non-Current Deffered Revenue of $500000.0 for Q4 2025, little changed year-over-year from $500000.0 in Q4 2024, and little changed quarter-over-quarter from $500000.0 in Q2 2025.
RedHill Biopharma (RDHL) Non-Current Deffered Revenue (2018 - 2025) Analysis & Trends
RedHill Biopharma (RDHL) has 8 years of Non-Current Deffered Revenue data on file, last reported at $500000.0 in Q4 2025.
- Non-Current Deffered Revenue for Q4 2025 came in at $500000.0, changed 0.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $500000.0 (changed 0.0% YoY), and the FY2025 annual result was $500000.0, changed 0.0% from the prior year.
- Non-Current Deffered Revenue steadied at $500000.0 in Q4 2025 per RDHL's latest filing, from $500000.0 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $750000.0 in Q1 2021 and troughed at $500000.0 in Q4 2024.
- A 5-year average of $672000.0 and a median of $750000.0 in 2021 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2021 and 2023: Non-Current Deffered Revenue soared 50.0% in 2021, then declined 28.0% in 2023.
- A 5-year view of Non-Current Deffered Revenue shows it stood at $750000.0 in 2021, then changed by 0.0% to $750000.0 in 2022, then decreased by 28.0% to $540000.0 in 2023, then dropped by 7.41% to $500000.0 in 2024, then changed by 0.0% to $500000.0 in 2025.
- Business Quant data shows RDHL's Non-Current Deffered Revenue at $500000.0 in Q4 2025, $500000.0 in Q2 2025, and $500000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | RedHill Biopharma | 119.32 Mn | 119.32 Mn | - | 500,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 500,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Jun 30, 2024 | 540,000.00 |
| Dec 31, 2023 | 540,000.00 |
| Jun 30, 2023 | 750,000.00 |
| Mar 31, 2023 | 750,000.00 |
| Dec 31, 2022 | 750,000.00 |
| Sep 30, 2022 | 750,000.00 |
| Jun 30, 2022 | 750,000.00 |
| Mar 31, 2022 | 750,000.00 |
| Dec 31, 2021 | 750,000.00 |
| Sep 30, 2021 | 750,000.00 |
| Jun 30, 2021 | 750,000.00 |
| Mar 31, 2021 | 750,000.00 |
| Dec 31, 2020 | 750,000.00 |
| Sep 30, 2020 | 500,000.00 |
| Jun 30, 2020 | 500,000.00 |
| Mar 31, 2020 | 500,000.00 |
| Dec 31, 2019 | 500,000.00 |